Trial reportInternational journal of colorectal disease2013
Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis.
Trial report in International journal of colorectal disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- European Guideline on Pre-Operative Prevention of Surgical Site Infections Following Digestive Surgery: A Joint Update of the WHO SSI Guideline for Gastrointestinal Surgery by UEG, ESCP, EAES, and SIS-E.United European gastroenterology journal · 2025Guideline
- Perioperative Management of Ulcerative Colitis: A Systematic Review.Diseases of the colon and rectum · 2022Pooled it
- The Japan Society for Surgical Infection: guidelines for the prevention, detection, and management of gastroenterological surgical site infection, 2018.Surgery today · 2021Pooled it
- Pooled it
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.United European gastroenterology journal · 2019Pooled it
- Comparative Risk of Complications Following Intestinal Surgery After Infliximab, Vedolizumab, or Ustekinumab Treatment: Systematic Review & Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Clinical evaluation of platelet-to-albumin ratio as a predictor of surgical site infection in pediatric patients with ulcerative colitis.Surgery today · 2025Article
- Have advances in medical therapy for ulcerative colitis impacted surgical treatment?Annals of gastroenterological surgery · 2023Article
- The Effect of Anti-Tumor Necrosis Factor-Alpha Therapy within 12 Weeks Prior to Surgery on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample.Digestive diseases and sciences · 2021Article
- Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review.Journal of clinical medicine · 2021Review
- Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics.International journal of colorectal disease · 2019Article
- Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan.Surgery today · 2016Article
- Inflammatory bowel disease surgery in the biologic era.World journal of gastrointestinal surgery · 2016Review
- Preoperative Corticosteroid Usage and Hypoalbuminemia Increase Occurrence of Short-term Postoperative Complications in Chinese Patients with Ulcerative Colitis.Chinese medical journal · 2016Article
- Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper.Inflammatory bowel diseases · 2015Review
- [Refractory inflammatory bowel disease: surgical challenges].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe high incidence of infectious complications in ulcerative colitis (UC) is generally recognized to be due to several factors related to a compromised host. In our previous study, a high dose of corticosteroid was shown to be a risk factor for surgical site infection (SSI). Recently, infliximab (IFX) has been used for refractory UC. In this study, the effect of IFX on the occurrence of infectious postoperative complications for UC was evaluated, because it remains controversial.
methodA total of 196 UC patients who underwent laparotomy between January 2010 and September 2012 were included. Possible factors related to complications were analyzed to identify significant predictors.
resultsTwenty-two patients had IFX before surgery. The overall incidence of SSI was 47/196 (24.0 %). The incidence of infections, including SSI and other infections, was 69/196 (35.2 %). On multivariate analysis, national nosocomial infection surveillance (NNIS) risk index ≥2 (p<0.01) and preoperative prednisolone dose ≥0.2 mg/kg/day (p = 0.01) were identified as independent risk factors for overall SSI; NNIS risk index ≥2 (p <0.01) and duration from onset of UC ≥6.3 years (p = 0.045) were identified as independent risk factors for incisional SSI; contaminated wound class (p <0.01), preoperative hospital stay ≥6 days (p = 0.048), severe/fulminant disease activity (p = 0.04), and pancolitis (p = 0.02) were identified as independent risk factors for organ/space SSI; and contaminated wound (p < 0.01), severe/fulminant disease activity (p = 0.02), and age at surgery ≥43 years (p = 0.047) were identified as independent risk factors for total infectious complications.
conclusionIFX administration was not associated with infectious complications for UC surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.